Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
In its announcement, the company did not specify why Kawas’ doctoral research was under investigation, only saying it did not intend to comment on the issue until it had been resolved.
Eisai believes this is a potential-best in class FRα ADC that has shown single agent activity in patients with advanced solid tumors, including endometrial, ovarian, lung and breast cancers.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.